LONDON, Oct. 23,
2024 /PRNewswire/ -- Virax Biolabs Group Limited
(NASDAQ: VRAX) ("Virax" or the "Company"), an innovative
biotechnology company focused on the detection of immune responses
and diagnosis of viral diseases, today announced that it has
entered into a distribution agreement with Europa Biosite to
commercialize the company's ImmuneSelect Research Use portfolio in
the United Kingdom and
Ireland through its wholly owned
subsidiary Cambridge Bioscience.
"ImmuneSelect is an important suite of profiling solutions for
assessing adaptive immunity and we are pleased to partner with
Europa Biosite, a leader in life science distribution across
Europe," said James Foster, CEO of Virax Biolabs. "We
believe this partnership will meaningfully expand our commercial
footprint in the UK and Ireland
and make ImmuneSelect accessible to researchers and pharmaceutical
companies as they work to better understand the role of T cell
response and immune status."
"We are happy to partner with innovative companies like Virax
Biolabs," commented Martijn Blommaart, Director of Supplier
Development at Europa Biosite. "We look forward to leveraging
our commercial infrastructure to quickly deliver and provide local
technical support to ensure that ImmuneSelect is available in the
UK & Ireland"
About ImmuneSelect
ImmuneSelect is the Company's portfolio of research products
dedicated to investigating adaptive immunity. Products within the
ImmuneSelect brand are for research and investigational use only
and are not intended to be used as a diagnostics tool. The
ImmuneSelect portfolio includes peptide pools covering epitopes
from pathogens, optimized for the stimulation of T cells. The
initial offerings include pools for SARS-CoV-2, SARS-CoV-2 MHC-1
("CD8"), Lyme Disease, Cytomegalovirus ("CMV"), Respiratory
Syncytial Virus ("RSV") and Epstein-Barr Virus ("EBV"), which
continue to be regularly expanded. ImmuneSelect's Recombinant
Antibodies target cytokines and biomarkers, and they are available
in different versions unconjugated to be tested on a range of
applications including Flow Cytometry, ELISA and
ELISpot/Fluorospot. ImmuneSelect is affordable, easy to use, and is
compatible with most standard laboratory equipment.
About Europa Biosite
Europa Biosite is a European supplier of life science products
and services, composed of six leading distribution companies:
Biomol in Germany, Cambridge
Bioscience in the UK and Ireland,
LubioScience in Switzerland,
Nordic Biosite in the Nordics and Baltics, Sanbio in Benelux and
Szabo-Scandic in Austria. The
group has a portfolio of over 5 million products, representation in
16 European countries and a highly skilled team of over 150
employees. Europa Biosite is the optimal gateway into the European
life science market, maximising sales growth through locally
tailored solutions and close supply partnerships.
For more information, please visit
https://www.europabiosite.com/.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology
company focused on the detection of immune responses to and
diagnosis of viral diseases. Virax Biolabs Group Limited is
currently developing T-Cell-based test technologies with the
intention of providing an immunology profiling platform. T-Cell
testing can be particularly effective in the diagnosis and
therapeutics of post-viral syndromes such as Long COVID and other
chronic conditions linked to immune dysregulation.
For more information, please
visit www.viraxbiolabs.com.
Investor Relations Contact:
Russo Partners,
LLC
Nic Johnson
12 West 27th Street
4th Floor
New York, NY 10001
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-announces-distribution-agreement-with-europa-biosite-to-commercialize-immuneselect-in-the-united-kingdom-and-ireland-302283521.html
SOURCE Virax Biolabs
